These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 27650684)
1. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Wright AA; Bohlke K; Armstrong DK; Bookman MA; Cliby WA; Coleman RL; Dizon DS; Kash JJ; Meyer LA; Moore KN; Olawaiye AB; Oldham J; Salani R; Sparacio D; Tew WP; Vergote I; Edelson MI Gynecol Oncol; 2016 Oct; 143(1):3-15. PubMed ID: 27650684 [TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Wright AA; Bohlke K; Armstrong DK; Bookman MA; Cliby WA; Coleman RL; Dizon DS; Kash JJ; Meyer LA; Moore KN; Olawaiye AB; Oldham J; Salani R; Sparacio D; Tew WP; Vergote I; Edelson MI J Clin Oncol; 2016 Oct; 34(28):3460-73. PubMed ID: 27502591 [TBL] [Abstract][Full Text] [Related]
3. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept. Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504 [TBL] [Abstract][Full Text] [Related]
4. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy. Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648 [TBL] [Abstract][Full Text] [Related]
5. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). Reuss A; du Bois A; Harter P; Fotopoulou C; Sehouli J; Aletti G; Guyon F; Greggi S; Mosgaard BJ; Reinthaller A; Hilpert F; Schade-Brittinger C; Chi DS; Mahner S Int J Gynecol Cancer; 2019 Oct; 29(8):1327-1331. PubMed ID: 31420412 [TBL] [Abstract][Full Text] [Related]
6. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer. Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). Glasgow MA; Yu H; Rutherford TJ; Azodi M; Silasi DA; Santin AD; Schwartz PE J Surg Oncol; 2013 Feb; 107(2):195-200. PubMed ID: 22648987 [TBL] [Abstract][Full Text] [Related]
8. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510 [TBL] [Abstract][Full Text] [Related]
9. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database. Rauh-Hain JA; Melamed A; Wright A; Gockley A; Clemmer JT; Schorge JO; Del Carmen MG; Keating NL JAMA Oncol; 2017 Jan; 3(1):76-82. PubMed ID: 27892998 [TBL] [Abstract][Full Text] [Related]
10. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Maheshwari A; Kumar N; Gupta S; Rekhi B; Shylasree TS; Dusane R; Bajpai J; Ghosh J; Gulia S; Deodhar K; Menon S; Popat P; Sable N; Thakur M; Kerkar R Indian J Cancer; 2018; 55(1):50-54. PubMed ID: 30147093 [TBL] [Abstract][Full Text] [Related]
11. Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer-A National Cancer Database Study. Leiserowitz GS; Lin JF; Tergas AI; Cliby WA; Bristow RE Int J Gynecol Cancer; 2017 May; 27(4):675-683. PubMed ID: 28328580 [TBL] [Abstract][Full Text] [Related]
12. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer. Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454 [TBL] [Abstract][Full Text] [Related]
14. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245 [TBL] [Abstract][Full Text] [Related]
15. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer. Luo Y; Lee M; Kim HS; Chung HH; Song YS Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness. da Costa Miranda V; de Souza Fêde ÂB; Dos Anjos CH; da Silva JR; Sanchez FB; da Silva Bessa LR; de Paula Carvalho J; Filho EA; de Freitas D; Del Pilar Estevez Diz M Gynecol Oncol; 2014 Feb; 132(2):287-91. PubMed ID: 24333355 [TBL] [Abstract][Full Text] [Related]
17. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556 [TBL] [Abstract][Full Text] [Related]
18. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269 [TBL] [Abstract][Full Text] [Related]
19. Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer. Lim MC; Yoo HJ; Song YJ; Seo SS; Kang S; Kim SH; Yoo CW; Park SY J Gynecol Oncol; 2017 Jul; 28(4):e48. PubMed ID: 28541636 [TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer. Taşkın S; Güngör M; Ortaç F; Öztuna D Arch Gynecol Obstet; 2013 Dec; 288(6):1399-403. PubMed ID: 23775264 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]